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Abstract: Multiple myeloma (MM) is an incurable disease caused by the malignant proliferation
of bone marrow plasma cells, whose pathogenesis remains largely unknown. Although a large
fraction of the genome is actively transcribed, most of the transcripts do not serve as templates
for proteins and are referred to as non-coding RNAs (ncRNAs), broadly divided into short and
long transcripts on the basis of a 200-nucleotide threshold. Short ncRNAs, especially microRNAs,
have crucial roles in virtually all types of cancer, including MM, and have gained importance in cancer
diagnosis and prognosis, predicting the response to therapy and, notably, as innovative therapeutic
targets. Long ncRNAs (lncRNAs) are a very heterogeneous group, involved in many physiological
cellular and genomic processes as well as in carcinogenesis, cancer metastasis, and invasion.
LncRNAs are aberrantly expressed in various types of cancers, including hematological malignancies,
showing either oncogenic or tumor suppressive functions. However, the mechanisms of the related
disease-causing events are not yet revealed in most cases. Besides emerging as key players in
cancer initiation and progression, lncRNAs own many interesting features as biomarkers with
diagnostic and prognostic importance and, possibly, for their utility in therapeutic terms as druggable
molecules. This review focuses on the role of lncRNAs in the pathogenesis of MM and summarizes
the recent literature.
Keywords: long non-coding RNAs (lncRNAs); multiple myeloma (MM); expression profiling;
transcription regulation
1. Introduction
Multiple myeloma (MM) is a fatal malignant proliferation of antibody-secreting bone marrow (BM)
plasma cells (PCs) that accounts for 10% of all hematological malignancies with an incidence in
western countries of about 3–5 per 100,000. MM is characterized by an extensive clinical variety
ranging from the presumed premalignant condition, called monoclonal gammopathy of undetermined
significance (MGUS), to extramedullary myeloma and plasma cell leukemia (PCL) [1–3]. Despite the
remarkable improvements in the treatment and patient care [4], MM remains an incurable disease.
MM shows a high genomic time- and phase-dependent instability and consequently a very complex
karyotype that leads this plasma cell dyscrasia to more resemble solid than haematologic tumors [1,5,6].
Nearly half of MM tumors are hyperdiploid, associated with nonrandom trisomies of odd chromosomes.
The remaining tumors are non-hyperdiploid and frequently associated with the constitutive activation
of CCND1 (11q13), CCND3 (6p21), MAF (16q23), MAFB (20q11), or FGFR3/MMSET (4p16.3) genes
consequent to chromosomal translocations involving the immunoglobulin heavy-chain locus (IGH) on
chromosome 14q32. The mechanisms underlying this dichotomic pattern have not been elucidated yet.
Hyperdiploid patients have a generally better prognosis, whereas the t(4;14) and t(14;16) translocations
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are associated with a poor prognosis, either under conventional or high-dose therapy. In addition,
allelic imbalances of specific genomic regions, including 13q, 17p13, 1p, 16q, 14q losses and 1q gains,
are adversely linked to prognosis [5,6]. The high-risk chromosomal aberrations del (17p13), t(4;14),
and 1q21 have been identified as adverse prognostic factors also in asymptomatic smoldering MM
(SMM), independent of the tumor burden, whereas hyperdiploidy, contrary to active myeloma,
seems to be an adverse prognostic factor in SMM [7]. Overall, transcriptional data have provided
valuable information on the genes aberrantly expressed in MM, further supporting their high biological
heterogeneity and showing their promising prognostic role [8].
During the last two decades of research, thanks to the impressive development and application of
high-throughput sequencing techniques, it has been demonstrated that, although a large fraction of the
human genome is actively transcribed [9,10], non-coding RNAs (ncRNAs), namely the RNA fraction
not translated into canonical functional proteins, account for the majority of transcripts. Increasing
evidence suggests their huge impact on several molecular mechanisms: in particular, the roles of
ncRNAs in supporting cellular homeostasis and gene expression regulation and in governing different
pathologies are recently emerging.
According to their size, ncRNAs have been arbitrarily categorized into short and long ncRNAs
(lncRNAs), the latter being longer than 200 nucleotides. Short ncRNAs can be further subdivided
into various categories, including microRNAs (miRNAs), small interfering RNAs, PIWI-associated
RNAs and small nucleolar RNAs. Dysregulated short ncRNAs, especially miRNAs, are known to
have important functions in virtually all types of cancer, including MM. Further, miRNA profiling
has assumed a crucial value in tumor diagnosis and prognosis and in predicting the response to
therapy [11]. Notably, miRNAs have also gained importance as innovative therapeutic targets in
cancer, including MM [12–14].
LncRNAs are a heterogeneous group representing more than half of the mammalian non-coding
transcriptome. They participate in various biological processes, such as transcriptional gene
regulation, maintenance of genomic integrity, X-chromosome inactivation, genomic imprinting,
cell differentiation, and development. LncRNAs are transcribed from introns, exons, intergenic
or intra-genic regions, promoter regions, 3′- and 5′-UTRs; therefore, they may represent intronic,
intergenic, bidirectional, and antisense- or sense-overlapping sequences [15,16]. The catalog of known
human lncRNA genes and transcripts has been growing impressively over the last few years and is still
evolving. The largest repositories currently contain more than 60,000 human annotated lncRNA genes
(e.g., 65,694 LNCpedia v4.1; 96,308 Noncode v5.0), with many loci generating multiple transcripts.
Such a discrepancy is mainly attributable to the wide or stringent criteria used to include sequences
based on RNA-sequencing studies predictions [17,18].
Not greatly different from mRNAs as it regards structure and biogenesis, lncRNAs can be
polyadenylated and may operate in either nuclear or cytoplasmic fractions. Their expression is
developmentally regulated and it is restricted to specific cell or tissue types to a greater extent
than mRNA [15]. The adaptability due to their secondary structure allows lncRNAs to form
binding sites for the interaction with proteins, DNA, and other RNA molecules. Thanks to specific
substructures, lncRNAs can then function as guides, tethers, decoys, and scaffolds. LncRNAs can
regulate gene expression at three levels, specifically, the transcriptional, post-transcriptional, and
chromatin modification levels [16,19–24]. Although the mechanisms underlying the function of
most lncRNAs are not fully understood, the deregulation of distinct lncRNAs has been reported to
promote tumor formation, progression, and metastasis in many types of cancer, including hematologic
malignancies [20,21]. Interestingly, because of their presence in body fluids, including urine and
blood, although at a low level of expression, circulating cell-free lncRNAs are promising putative
non-invasive diagnostic and prognostic biomarkers in cancer patients [25].
Even though it is still in its beginnings, the knowledge of the role of lncRNAs in MM is
progressively expanding. In this review, we provide a compendium of the lncRNAs reported to
be deregulated in MM and, therefore, putatively implicated in its pathogenesis and clinical outcome.
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2. LncRNAs in Multiple Myeloma
2.1. MALAT1
The expression of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), a putative
oncogenic lncRNA transcribed from chromosome 11q13 and overexpressed in several solid
tumors [26,27], was firstly investigated by Cho et al. [28] in BM mononuclear cells from MM patients
with different disease status at diagnosis, showing its significant overexpression compared to normal
controls. Moreover, patients who relapsed or had disease progression showed a significant increased
expression of MALAT1. These findings were further supported by Ronchetti et al. investigating,
by expression microarray, a large cohort of patients encompassing all the major different forms of
PC dyscrasias: notably, an association was found between MALAT1 upregulation and molecular
pathways involved in cell cycle regulation, p53-mediated DNA damage response, and mRNA
maturation processes [29]. More recently, other groups found high expression levels of MALAT1
in BM mononuclear cells from untreated MM patients with different disease status, as well as in MM
cell lines, along with a significant reduction of its expression in complete remission patients [30–32].
In the study from Gao et al. [30], the expression trend of MALAT1 strictly resembled that of the
DNA-binding protein high mobility group box 1 (HMGB1), which acts as a mediator of autophagy
in the cytoplasm. HMGB1 was previously found overexpressed in MM and shown to sustain the
survival and proliferation of myeloma cells [33]. MALAT1 knockdown in MM cell lines and in a mouse
model [30] reduced HMGB1 expression levels as well as the expression of Beclin-1 and LC3B, both
related to autophagy. The direct binding between MALAT-1 and HMGB1 might be partially responsible
for an increased ubiquitination and degradation of the protein. MALAT1 knockdown promoted also
a significant reduction of viability and an increase of apoptosis in MM cells, whereas the combined
HMGB1 overexpression was able to abolish all the mentioned effects. These findings suggest that
MALAT1 favors autophagy in MM by upregulating HMGB1 expression, thus supporting its role in
the suppression of apoptosis and the promotion of tumor cell survival. The induction of apoptosis
in MALAT1-silenced cells might involve a down-regulation of cyclin D1 and cyclin E, the activation
of caspase-3 and caspase-9, the increased level of the pro-apoptotic protein BAX, and the decreased
level of the anti-apoptotic protein BCL-2 [31]. Worth noting is also that MALAT1 has been recently
linked with the extramedullary dissemination of MM, often developing after several chemotherapeutic
interventions and associated with a worse prognosis: not only a substantially greater expression
of MALAT1 was found in extramedullary MM, but even higher expression levels were shown in
extramedullary PCs matched with the intramedullary ones from the same patients [32]. These findings
extend previous data [29], thus suggesting a role for MALAT1 in extramedullary dissemination.
This hypothesis was further supported by the correlation of higher MALAT1 expression with worse
overall and progression-free survival (OS and PFS); in particular, MALAT1 expression showed
an independent influence on PFS, suggesting a possible role in drug resistance [32]. Furthermore,
the positive correlation between the expression levels of MALAT1 and heat shock protein 90 s (known to
be induced in response to diverse cellular stress), together with the in vitro demonstration of MALAT1
upregulation after treatment with proteasome inhibitors and doxorubicin, suggested that MALAT1
overexpression might depend on, or at least be related to, the chemotherapeutic stress response [32].
Finally, MALAT1 was recently shown to be overexpressed in mesenchymal stromal cells
(MSCs) from MM patients, which led to the transcriptional activation of the neighboring antisense
protein-coding gene LTBP3 (latent TGF-β-binding protein) [34]. LTBP3 is acknowledged as a positive
regulator of the activity of TGF-β, which may get involved in the inhibition of terminal
osteoblastogenesis in MM [35]. Actually, it was demonstrated that MALAT1 recruits the transcription
factor SP1 on the LTBP3 promoter, thus contributing to the increase of LTBP3 expression. Conversely,
a significant reduction of LTBP3 transcription followed MALAT1 knockdown [34].
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2.2. MEG3
MEG3 (maternally expressed gene 3) lncRNA, located at 14q32.2, is thought to act as a tumor
suppressor through both p53-dependent and p53-independent mechanisms and to be controlled
epigenetically at the expression level [36,37]. Studying the expression of MEG3 in MM, Benetatos et al.
observed hypermethylation of the differentially methylated region (DMR) of the MEG3 promoter in
about 60% of patients, which correlated with both disease stage and subtype [38]. Two-third of the
patients with IgG MM and all of those with IgM exhibited the epigenetic alteration, whereas none of
the patients with IgA had hypermethylated DMR. These findings led to suggest a possible involvement
of MEG3 lncRNA promoter hypermethylation and, consequently, of its reduced expression in MM
tumorigenesis. Of interest, MSCs from MM patients (MM-MSCs) expressed MEG3 to a lesser degree
than those from normal donors (ND-MSCs) throughout osteogenic differentiation [39]. Moreover,
the overexpression of MEG3 was able to stimulate MM-MSCs to differentiate, while MEG3 knockdown
had a negative effect on the osteogenesis of ND-MSCs. On the basis of experimental investigations,
MEG3 promoted osteogenesis by targeting the transcription of BMP4 (bone morphogenetic protein 4),
a gene member of the TGF family. Both MEG3 and BMP4 map to chromosome 14, albeit with
divergent transcription orientation. MEG3 is supposed to interact directly with the transcription factor
SOX2, triggering its separation from the BMP4 promoter and then determining an increase of BMP4
expression [39].
2.3. CRNDE
CRNDE (colorectal neoplasia differentially expressed), a lncRNA mapped at 16q12.2, was firstly
recognized as upregulated in colorectal cancer [40]. Subsequently, the elevated expression of this
lncRNA was found in the early stages of human development, in several solid tumors, as well as in
leukemias and MM [41]. In their recent study, Meng et al. [42] found increased expression of CRNDE in
MM cell lines and patients, associated with poor OS. CRNDE knockdown in U266 and RPMI-8226 cell
lines inhibited proliferation and colony formation and led to increased apoptosis and cell cycle arrest in
G0/G1 phase. The knockdown of CRNDE in U266 cells was associated with a considerable increment
of miR-451 expression, otherwise downregulated in MM patients compared with normal controls.
By means of bioinformatics analysis and dual-luciferase reporter assay, a putative complementary
interaction between miR-451 and the 3′-UTR of CRNDE was shown. Furthermore, Meng et al. found
a negative correlation of CRNDE with miR-451 in MM patients, suggesting that CRNDE might act in
MM pathogenesis by negatively targeting miR-451. This hypothesis was reinforced by the observation
that miR-451 inhibition was able to rescue the above described effects of CRNDE knockdown in U266
cell line, thus restoring the tumorigenesis of the cells [42].
2.4. UCA1
A possible prognostic impact of the expression level of lncRNA UCA1 (urothelial cancer
associated 1) in MM was recently postulated by Sedlarikova et al. [43] in a study analyzing the
expression of 83 candidate lncRNAs in BM PCs of newly diagnosed MM patients compared to
normal BM PCs of healthy donors (HD). Specifically, of the 27 lncRNAs identified as differentially
expressed in MM patients, UCA1 resulted significantly downregulated in MM samples compared
to HD, also showing a negative and a positive correlation with albumin and monoclonal-Ig serum
levels, respectively. Moreover, in MM patients higher levels of UCA1 correlated with poorer OS and
the occurrence of 1q21 gain or t(4;14) translocation, known unfavorable prognostic features of MM.
UCA1, mapped at 19p13.12, was firstly identified as greatly expressed in bladder transitional
cell carcinoma [44]. A link between UCA1 and the transcription factor CREB (cAMP response
element-binding protein) was found in bladder cancer cells [45] indicating that UCA1 might influence
cell cycle regulation by activating CREB via PI3K–AKT pathway.
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2.5. OIP5-AS1
Yang et al. discovered an inverse correlation between the high levels of miR-410 expression
in newly diagnosed MM and lncRNA OIP5-AS1 (OIP5 antisense RNA 1), mapped on chromosome
15q15.1 [46]. Experimental evidences indicated that OIP5-AS1 was able to inversely modulate the
expression of miR-410 and its pro-oncogenic effects on cell proliferation, cell cycle progression,
and apoptosis in NCI-H929 and RPMI-8226 cell lines. On the basis of the identification of KLF10
(Kruppel Like Factor 10), involved in PTEN–AKT signaling activation, as a direct downstream target of
miR-410 in MM, it was further demonstrated the contribution of OIP5-AS1 in the KLF10–PTEN–AKT
signaling pathway in MM cells, very likely through a negative regulation of miR-410. Overall, the loss
of lncRNA OIP5-AS1 induced miR-410 accumulation in MM cells leading to cell proliferation, cell cycle
progression, and apoptosis inhibition via the KLF10–PTEN–AKT signaling axis.
3. lncRNA Expression Profiles in MM
Studies investigating the global lncRNA expression in MM are still limited and based on
microarray data. In particular, there are two different studies concerning the same publicly available
microarray datasets including a large group of 559 MM patients, profiled onto GeneChip® 3′-in vitro
transcription arrays querying the poly-A+ fraction of transcripts [47,48]. In the first investigation,
Zhou et al. [47] examined a list of 2330 lncRNA by re-annotating such datasets and identified
a four-lncRNA prognostic signature able to predict survival in MM patients. In particular, two lncRNAs,
RP1-43E13.2 and RP4-803J11.2, are located on chromosome 1p and 1q, respectively, frequently lost
or gained in MM and related with poor prognosis [6,49–51]. The second study, based on custom
lncRNA-oriented annotation files of the same datasets, identified 176 lncRNAs able to clusterize
patients into two groups with significant differences in terms of OS [48] and predict the patient’s
prognosis independently from β2-microglobulin, albumin, and LDH serum levels.
Ronchetti et al. [29], by employing new-generation whole-transcript arrays, analyzed the global
lncRNA expression profiles in a group of 259 patients, representative of all the main forms of
PC dyscrasias, which included MGUS, asymptomatic SMM, truly overt and symptomatic MM,
extra-medullary MM/PCL patients, together with nine HD. Among the 1852 lncRNAs queried by
unique probes on the array, 230 were capable to discriminate normal and pathological samples and
the different forms of PC dyscrasias. A group of 31 lncRNAs, including MALAT1, was specifically
dysregulated in pathological specimens in comparison to normal BM PCs. In addition, the expression
of 21 lncRNAs showed a progressive deregulation linked to the aggressiveness of the disease (Figure 1).
In particular, lnc-SENP5-4, lnc-CPSF2-2, and lnc-LRRC47-1 displayed a significantly different expression
when a group of 19 MMs at diagnosis was matched with the corresponding relapse–PCL phases.
Interestingly, the downregulation of lnc-LRRC47-1 from normal PCs to MGUS and symptomatic
myeloma was reported also by others [52]. The panel of 21 lncRNA included GAS5 (growth
arrest-specific 5), mapped at 1q25, a tumor suppressor-like associated with cell cycle arrest and
apoptosis [53–57]. Interestingly, GAS5 was also significantly upregulated in MMs showing 1q gain,
together with other six specific lncRNAs. Patients with del13 had a significant downregulation of
DLEU2 (deleted in leukemia 2), mapping at 13q14.3 and hosting the cell cycle inhibitory miRNAs
15a and 16-1 [58]. A significant correlation of DLEU2 with miR-15a and miR-16-1 expression
was shown. These findings support a gene-dose effect as a probable mechanism conditioning
lncRNAs deregulation.
Finally, Ronchetti et al. expanded their investigation on the function of lncRNA dysregulation in
PC dyscrasias by analyzing the association miRNA–lncRNA in MM, PCL, and normal PCs samples.
The identification of lncRNA–miRNA pairs (lnc-MCL1-2 and mir-17 gene family; lnc-AGBL1-4 and
mir-185-5p; lnc-DLEU2 and miR-3175; LINC00173 and miR-221) with a possible important interplay
for MM biology, suggested an influence of miRNA–lncRNA communication on MM pathology [59].
A selection of lncRNAs deregulated in MM with potential relevance in the pathology is reported
in Table 1.
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represented. The relative expression level (scaled to common y-axis range on the upper and lower values) of the long ncRNAs (lncRNAs) deregulated through the 
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Table 1. Overview of selected lncRNAs with a putative pathogenetic role in multiple myeloma (MM).
lncRNA(s)/Alias Loc Func a Molecular Mechanism Ref(s). Tissue Pts (n) b Method(s)
DLEU2 13q14.3 TS
Host of miR-15a/16-1 cluster
targeting BCL2.
[29] bone marrow (BM) plasma-cells (PCs) 259 + 9 healthy donors Gene expression profiling
[58] chronic lymphocytic leukemia (CLL) 7 CLL (and 1 CLL cell line) RT-PCR
GAS5 1q25.1 TS
Required for the inhibitory
effects of mTOR antagonists.
Regulated by mTOR pathway.
[29] BM PCs 259 + 9 healthy donors Gene expression profiling
[53] embryo and adult mouse tissues;Friend leukemia cells N/A Northern blot analysis; in situ hybridization
[57] paired tumor and adjacent normalbreast epithelial tssues 21 (and several mammalian cell lines) Semiquantitative and qRT-PCR
[54] lymphocytes from diffuse largeB-cell lymphoma 1 RT-PCR
[55] renal cell carcinoma (RCC) 12 (and 1 RCC cell line + 1nonmalignant renal cell line) qRT-PCR
[56] paired non-small cell lung cancer andadjacent normal lung tissue 72 qRT-PCR
MALAT1 11q13 O
SP1 recruitment to the promoter
of LTBP3 gene regulating the
bioavailability of TGF-β.
[26] Hela cells N/A qRT-PCR
[27] HepG2 and HeLa cell lines N/A RT-PCR, immunofluorescence
[28] BM mononuclear cells fromMM patients 124 + 20 healthy donors qRT-PCR
[29] BM PCs 259 + 9 healthy donors Gene expression profiling
[30] BM mononuclear cells fromMM patients
60 + 10 healthy donors (and 2 MM
cell lines) qRT-PCR
[31] MM cell lines not applicable RT-PCR
[32] BM and extramedullary PCs 162 (and 5 MM cell lines) RT-PCR
[34] BM mesenchymal stromal cells fromMM patients 25 + 5 healthy donors qRT-PCR
MEG3 14q32.2 TS
Interaction with p53.
Regulation of P53 gene
expression. Enhancement of the
expression of BMP4 gene in
MM-MSCs.
[36] Human colon carcinoma andosteosarcoma cell lines N/A RT_PCR
[38] BM and peripheral blood fromMM patients 21 + 10 healthy donors Methylation-specific PCR
[39] BM mesenchymal stromal cells fromMM patients 6 + 3 healthy donors qRT-PCR
CRNDE 16q12.2 O Negative targeting of miR-451. [42] BM PCs 77 + 19 healthy donors (and 5 MMcell lines) qRT-PCR
UCA1 19p13.12 O
Cell cycle regulation by
activation of CREB via
PI3K-AKT pathway.
[43] BM PCs 84 + 22 healthy donors qRT-PCR
[45] Human bladder cancer cellline BLZ-211 Gene expression profiling
OIP5-AS1 15q51.1 O Molecular sponge modulatingmiR-410. [46] BM PCs
97 + 14 healthy donors (and 3 MM
cell lines) qRT-PCR
lnc-SENP5-4/NCBP2-AS2 3q29
U Not described. [29] BM PCs 259 + 9 healthy donors Gene expression profiling
lnc-CPSF2-2 14q32
lnc-LRRC47-1/TP73-AS1 1p36
lnc-ANGPTL1-3 1q25
lnc-WHSC2-2 4p16.3
Abbreviations: a U = Uncharacterized; O = Oncogene; TS = Tumor Suppressor; b Pts (n) = Patients (number). N/A: not applicable. BM = bone marrow; MSCs = mesenchymal stromal cells.
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4. Conclusions
LncRNAs are a large and composite family of transcripts that do not encode proteins, with an
emergent crucial role in a variety of processes accompanying the biology of normal and cancer cells.
Their tissue-specific expression and their easy detectability in body fluids confer them strong potential
as biomarkers in the diagnosis and prognosis of many cancer types. The investigation of lncRNAs in
MM is still limited, and more extensive profiling studies based on novel approaches, such as RNA
sequencing, are needed. In addition, among the dysregulated lncRNAs in MM identified so far,
only a few of them have been, at least in part, characterized. However, the available data suggest
central roles for lncRNAs in different stages of PC dyscrasias and prompt to explore their relevance
as prognostic biomarkers. Furthermore, the targeting of specific lncRNAs in MM have been scarcely
investigated until now, hence, a more thorough understanding of their functions and mechanisms in
the disease biology is certainly necessary. Improving the knowledge of the types and roles of different
lncRNAs in MM will clearly represent a significant step forward in the current comprehension of its
pathobiology. Indeed, it would provide valuable information about key cancer-promoting pathways
in MM and be useful for a better diagnostic and prognostic assessment. Furthermore, lncRNA
may represent excellent candidates for new anticancer approaches, mostly because of their cancer-
and tissue-specific expression that could confer major advantages over other therapeutic options.
Their better understanding in MM, may provide an important contribution for the development of
novel lncRNA-based therapies for the disease.
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